Dr. Andrew Brohl at ASCO 2023: Abstract No. 9534
2 Views
administrator
07/17/23
At ASCO 2023, Moffitt's Dr. Andrew Brohl discusses a phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.
-
Category
Show more
Facebook Comments
No comments found